Open Orphan - Contract signed with Carna Bioscience

Cathal Friel, Chief Executive of Open Orphan is pleased to announce the signing of a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve months.

Cathal Friel
CEO

Company Events - OPEN ORPHAN

Open Orphan Presentation

Cathal Friel, CEO

Wed, 9 Oct 2019, 7:00am BST